TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17350856

Group type: EXPERIMENTAL
Intervention: Preoperative ACEI or ARB use (175 patients)
Number of subjects: 338

Group type: COMPARATOR
Intervention: No preoperative ACEI or ARB use (163 patients)
Number of subjects: 338
Study: 16298736

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) at 1200 or 1800 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oxygen administration at 2 l/m for 18 h
Number of subjects: 45
Study: 9676460

Group type: EXPERIMENTAL
Intervention: HASTE MRI
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sonography
Number of subjects: 72
Study: 8034815

Group type: EXPERIMENTAL
Intervention: Verbal/stressful condition
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Written/stressful condition
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Verbal/stressful group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Written/trivial control group
Number of subjects: 57
Study: 2723355

Group type: EXPERIMENTAL
Intervention: Epidural analgesia started at the beginning of induction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Epidural analgesia started when labor became active
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Epidural analgesia timing in primiparous patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Epidural analgesia timing in multiparous patients
Number of subjects: 88
Study: 30080128

Group type: EXPERIMENTAL
Intervention: Motivational and reminder text messages sent twice a week for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: No text messages (control group)
Number of subjects: 42
Study: 27988868

Group type: EXPERIMENTAL
Intervention: 12-month weight loss intervention
Number of subjects: 14
Study: 25741153

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) after endoscopic papillary balloon dilatation (EPBD)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) after endoscopic sphincterotomy (EST)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) without any procedure
Number of subjects: 218

Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) after EPBD
Number of subjects: 218

Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) after EST
Number of subjects: 218

Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) without any procedure
Number of subjects: 218
Study: 24521887

Group type: EXPERIMENTAL
Intervention: LACJ (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + jinghuaweikang gelatin pearls 240 mg, twice daily for 10 days, then jinghuaweikang gelatin pearls 240 mg, twice daily for 14 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: LACB (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg, twice daily for 10 days)
Number of subjects: 90
Study: 21248360

Group type: EXPERIMENTAL
Intervention: Intra‐esophageal infusion of 5‐mL acidic solution (0.1 N HCl)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 18979719

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 0
Study: 16984212

Group type: EXPERIMENTAL
Intervention: Traxoprodil 100mg oral dose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil 50mg oral dose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil 300mg oral dose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil 50mg intravenous infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil 100mg intravenous infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil oral administration in poor metabolisers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traxoprodil oral administration in extensive metabolisers
Number of subjects: 17
Study: 12683359

Group type: EXPERIMENTAL
Intervention: Frontal patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Posterior parietal patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-brain-injured subjects (control)
Number of subjects: 3
Study: 10969351

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen, Remune (inactivated, gp120‐depleted immunogen in IFA)
Number of subjects: 10
Study: 8956766

Group type: COMPARATOR
Intervention: Control enteral formula (1 L/d for 7 days before surgery)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (1 L/d for 7 days before surgery, enriched with arginine, RNA, and omega-3 fatty acids)
Number of subjects: 40
Study: 8005921

Group type: EXPERIMENTAL
Intervention: Guargum (20 grams)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of Guargum (10 grams) and Acarbose (50 grams)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (without trial drugs)
Number of subjects: 50
Study: 10284954

Group type: EXPERIMENTAL
Intervention: 10-bed geriatric units with individualized interventions and multidisciplinary approach
Number of subjects: 0
Study: 28980870

Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 60

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 60
Study: 27717336

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (first feeding bolus with a polymeric diet (1 kcal/ml) via a feeding tube 3 hours after PEG placement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late enteral feeding (first feeding bolus 8 hours after PEG placement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 0
Study: 26263079

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site myomectomy (LESS-M)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic myomectomy (LM)
Number of subjects: 100
Study: 23439892

Group type: EXPERIMENTAL
Intervention: Child manikin model
Number of subjects: 45

Group type: COMPARATOR
Intervention: Adult manikin model
Number of subjects: 45
Study: 22051490

Group type: EXPERIMENTAL
Intervention: Uncoated brackets (group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adhesive precoated brackets (group B)
Number of subjects: 12
Study: 19168190

Group type: COMPARATOR
Intervention: Stable group
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Reached Confirmed Sustained Progression (RCSP) group
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 181
Study: 16536766

Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg for 4 weeks
Number of subjects: 34
Study: 14642684

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day for 8 weeks followed by 8 mg/day for 4 weeks)
Number of subjects: 84
Study: 11104336

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular techniques (stent‐supported angioplasty)
Number of subjects: 0
Study: 9436940

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) combined with chemotherapy
Number of subjects: 2286

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: IFN maintenance therapy
Number of subjects: 2286
Study: 8437779

Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 14
Study: 3676158

Group type: EXPERIMENTAL
Intervention: 50 mg Fe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30033619

Group type: EXPERIMENTAL
Intervention: FAB 10 (esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAB 7 (same as FAB 10 but for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA 10 (esomeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days, without bismuth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA 7 (same as FA 10 but for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAB 10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAB 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA 10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 0
Study: 27089872

Group type: EXPERIMENTAL
Intervention: Improved latrines
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Improved water and sanitation (after the second phase)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Sanitation Calendar recording by mothers or caregivers
Number of subjects: 1200
Study: 23184061

Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 82
Study: 22490404

Group type: EXPERIMENTAL
Intervention: Standard antithrombotic therapy for two weeks
Number of subjects: 40
Study: 20602497

Group type: EXPERIMENTAL
Intervention: Postoperative magnesium hydroxide as a laxative
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of laxative and ONS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study: 18523415

Group type: EXPERIMENTAL
Intervention: DM‐o 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DM‐fo 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BM 0.05%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP 0.05%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HC 1.0%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DM vehicles
Number of subjects: 0
Study: 15860070

Group type: EXPERIMENTAL
Intervention: Empowering in-service training program for foreign nurse aides (3-month duration)
Number of subjects: 35
Study: 12912783

Group type: EXPERIMENTAL
Intervention: Reduced-glycemic load diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reduced-fat diet
Number of subjects: 16
Study: 10533765

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 269

Group type: COMPARATOR
Intervention: Cefuroxime/metronidazole
Number of subjects: 269
Study: 8978112

Group type: EXPERIMENTAL
Intervention: Relative risk reduction presentation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Other presentations (absolute risk reduction, difference in event-free patients, number needed to treat)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Current treatment preferences
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Understanding of statistics
Number of subjects: 73
Study: 1590013

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) evaluation of stone density prior to ESWL
Number of subjects: 97

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 97
Study: 4017670

Group type: EXPERIMENTAL
Intervention: 2 ml of 100-proof vodka per kg of body weight in orange juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29804794

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with pasteurized raw egg white
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cooked egg white
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pasteurized raw egg white
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgE specific of ovomucoid titer <2.045kU/l
Number of subjects: 0
Study: 26774322

Group type: EXPERIMENTAL
Intervention: Cemented ISPs with an abutment screw access hole (study group)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Conventional cemented ISPs without access hole (control group)
Number of subjects: 393
Study: 24863631

Group type: EXPERIMENTAL
Intervention: 10-20 ml/kg FFP (FFP group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10-20 ml/kg 4% succinylated gelatin (Gelofusine, GEL group, n=50)
Number of subjects: 100
Study: 22207015

Group type: EXPERIMENTAL
Intervention: Guideline for initiation and maintenance of insulin infusions for hyperglycemia
Number of subjects: 0
Study: 20108171

Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 92
Study: 18378918

Group type: EXPERIMENTAL
Intervention: Autologous retransfusion drains
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard care with vacuum drain (Control)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study: 15948160

Group type: EXPERIMENTAL
Intervention: RT directly after BCS
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: RT after the third chemotherapy cycle
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: RT after the sixth chemotherapy cycle
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 1831

Group type: COMPARATOR
Intervention: 1-3 chemotherapy cycles
Number of subjects: 1831
Study: 11926969

Group type: EXPERIMENTAL
Intervention: DBP-Estimated dp/dt
Number of subjects: 36

Group type: COMPARATOR
Intervention: Doppler-derived dp/dt
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between DBP-Estimated and Doppler-derived dp/dt
Number of subjects: 36
Study: 10609711

Group type: EXPERIMENTAL
Intervention: Instrumented measurement of total AP displacement during loading to 125 N of AP force
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Instrumented measurement of total I-E rotation during loading to 4000 N-mm torque
Number of subjects: 41
Study: 8955656

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (10:1 dose ratio with epirubicin)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (epirubicin without dexrazoxane)
Number of subjects: 162
Study: 2008281

Group type: EXPERIMENTAL
Intervention: 1% prodrug
Number of subjects: 66

Group type: COMPARATOR
Intervention: 10% viscous phenylephrine hydrochloride (HCl)
Number of subjects: 66
Study: 6662683

Group type: EXPERIMENTAL
Intervention: azlocillin-gentamicin (AZ-G)
Number of subjects: 58

Group type: COMPARATOR
Intervention: ampicillin-gentamicin (AM-G)
Number of subjects: 58
Study: 31654944

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (TR) + usual care
Number of subjects: 850

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study: 29327180

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 13004

Group type: COMPARATOR
Intervention: Chemotherapy only (CT)
Number of subjects: 13004
Study: 26888417

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (3 g/day)
Number of subjects: 0
Study: 25195522

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (dGTE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study: 22698766

Group type: EXPERIMENTAL
Intervention: High-oleic canola oil (HOCO) diet
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXCO) diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Typical Western diet (WD)
Number of subjects: 34
Study: 20487234

Group type: EXPERIMENTAL
Intervention: IIEF-15 questionnaire
Number of subjects: 137
Study: 17509103

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lubiprostone 48 mcg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lubiprostone 72 mcg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 16307962

Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg and ethinyl estradiol (EE) 20 mcg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12088811

Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 100
Study: 9701720

Group type: EXPERIMENTAL
Intervention: Caffeine (3 times daily for 6 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine (acute ingestion)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine (chronic exposure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine withdrawal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7649960

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2539180

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 5 mg kg‐1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6‐hourly for 6 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir and oral acyclovir
Number of subjects: 82
Study: 773085

Group type: EXPERIMENTAL
Intervention: Amphotericin B lozenges
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorhexidine denture immersion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorhexidine sucking
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water denture soaking
Number of subjects: 100
Study: 31481110

Group type: EXPERIMENTAL
Intervention: Dedicated smoking cessation clinic
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care with ultrasound screening for fetal growth restriction
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care with ultrasound screening for growth restriction only if clinically indicated
Number of subjects: 450
Study: 28120017

Group type: EXPERIMENTAL
Intervention: Distal sciatic nerve block (DSB) out-of-plane with 30 ml of Mepivacaine 1%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Proximal sciatic nerve block (DSB) in-plane with 30 ml of Mepivacaine 1%
Number of subjects: 56
Study: 26545677

Group type: EXPERIMENTAL
Intervention: 12-week resistance circuit training programme, 3-days per week
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 23159875

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg oral mecamylamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21112719

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Programme (CDSMP)
Number of subjects: 0
Study: 18801802

Group type: EXPERIMENTAL
Intervention: Transfusion and standard oxygenator (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No transfusion and coated oxygenator (Group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion and coated oxygenator (Group 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No transfusion and standard oxygenator (Group 1)
Number of subjects: 40
Study: 17083268

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normotensive healthy volunteers
Number of subjects: 100
Study: 15554351

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (25 healthy female subjects)
Number of subjects: 33
Study: 11414530

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol via Jet nebulizer
Number of subjects: 53

Group type: COMPARATOR
Intervention: Albuterol aerosol via MDI-spacer
Number of subjects: 53
Study: 9209217

Group type: EXPERIMENTAL
Intervention: Standardized tutorial on the vallecula sign
Number of subjects: 52
Study: 8136620

Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Porcine insulin (PI)
Number of subjects: 10
Study: 2443539

Group type: EXPERIMENTAL
Intervention: 60 mg prednisone per day for 2 days before challenge
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31578808

Group type: EXPERIMENTAL
Intervention: Participation in the PARROT Ireland randomized controlled trial of a diagnostic test for preeclampsia (Placental Growth Factor)
Number of subjects: 19
Study: 29696921

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with fluoxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture combined with fluoxetine
Number of subjects: 42
Study: 27706466

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy (maintaining Pao2 between 70 and 100 mm Hg or Spo2 between 94% and 98%)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (allowing Pao2 values up to 150 mm Hg or Spo2 between 97% and 100%)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 434
Study: 24718282

Group type: EXPERIMENTAL
Intervention: Borderline total IgE
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Elevated total IgE
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Positive IgE to food allergens
Number of subjects: 827

Group type: COMPARATOR
Intervention: Self-reported allergies
Number of subjects: 827
Study: 23524500

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 197

Group type: COMPARATOR
Intervention: Thienopyridine
Number of subjects: 197
Study: 19766580

Group type: EXPERIMENTAL
Intervention: 1.0 T extremity MRI
Number of subjects: 53

Group type: COMPARATOR
Intervention: 1.5 T MRI
Number of subjects: 53
Study: 18984333

Group type: EXPERIMENTAL
Intervention: Scratch collapse test
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tinel's test
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Wrist flexion/compression test
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Elbow flexion/compression test
Number of subjects: 169
Study: 16750014

Group type: EXPERIMENTAL
Intervention: Gd-DTPA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 42
Study: 14671465

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme (low fat diet, regular exercise, smoking cessation, psychosocial support, education)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (routine outpatient clinic follow-up)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme
Number of subjects: 197